Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kilian M Gust

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Der Urologe. Ausg. A|November 26, 2021
[Locally advanced or oligometastatic bladder cancer-role of local treatment of the primary tumor and metastases]Katharina Rebhan, Kilian M Gust
Current Opinion in Urology|November 10, 2017
Biomarkers for immunotherapy in urological cancersKilian M Gust, Irene Resch, David D'Andrea
Memo|April 3, 2018
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancerIrene Resch, Shahrokh F Shariat, Kilian M Gust
Current Opinion in Urology|April 3, 2020
Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer managementKatharina Rebhan, Ekaterina Laukhtina, Shahrokh F Shariat, et al.
Translational Andrology and Urology|November 22, 2021
Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literatureKilian M Gust, Irene Resch, David D'Andrea, et al.
Current Opinion in Urology|May 27, 2020
Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancerKilian M Gust, Katharina Rebhan, Irene Resch, et al.
Urologic Oncology|April 25, 2018
A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancerAndrea Mari, Shoji Kimura, Beat Foerster, et al.
World Journal of Urology|June 28, 2018
Molecularly-driven precision medicine for advanced bladder cancerLaura-Maria Krabbe, Vitaly Margulis, Andres Jan Schrader, et al.
BJU International|January 18, 2019
Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancerDavid D'Andrea, Francesco Soria, Sonja Zehetmayer, et al.
World Journal of Urology|March 18, 2018
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancerFrancesco Soria, Andrea I Beleni, David D'Andrea, et al.
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Der Urologe. Ausg. A|November 26, 2021
[Locally advanced or oligometastatic bladder cancer-role of local treatment of the primary tumor and metastases]Katharina Rebhan, Kilian M Gust
Current Opinion in Urology|November 10, 2017
Biomarkers for immunotherapy in urological cancersKilian M Gust, Irene Resch, David D'Andrea
Memo|April 3, 2018
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancerIrene Resch, Shahrokh F Shariat, Kilian M Gust
Current Opinion in Urology|April 3, 2020
Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer managementKatharina Rebhan, Ekaterina Laukhtina, Shahrokh F Shariat, et al.
Translational Andrology and Urology|November 22, 2021
Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literatureKilian M Gust, Irene Resch, David D'Andrea, et al.
Current Opinion in Urology|May 27, 2020
Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancerKilian M Gust, Katharina Rebhan, Irene Resch, et al.
Urologic Oncology|April 25, 2018
A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancerAndrea Mari, Shoji Kimura, Beat Foerster, et al.
World Journal of Urology|June 28, 2018
Molecularly-driven precision medicine for advanced bladder cancerLaura-Maria Krabbe, Vitaly Margulis, Andres Jan Schrader, et al.
BJU International|January 18, 2019
Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancerDavid D'Andrea, Francesco Soria, Sonja Zehetmayer, et al.
World Journal of Urology|March 18, 2018
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancerFrancesco Soria, Andrea I Beleni, David D'Andrea, et al.
Pageof 5